medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Express yourself: Quantitative real-time PCR assays for rapid chromosomal antimicrobial resistance detection in *Pseudomonas aeruginosa*

Danielle E. Madden[1,2], Olusola Olagoke[1,2], Timothy Baird[2,3], Jane Neill[2,3], Kay A. Ramsay[4], Tamieka A. Fraser[1,2], Scott C. Bell[4,5,6], Derek S. Sarovich[1,2*], and Erin P. Price[1,2*]

[1]Centre for Bioinnovation, University of the Sunshine Coast, Sippy Downs, Queensland, Australia

[2]Sunshine Coast Health Institute, Birtinya, Queensland, Australia

[3]Respiratory Department, Sunshine Coast University Hospital, Birtinya, Queensland, Australia

[4]Child Health Research Centre, The University of Queensland, South Brisbane, Queensland, Australia

[5]Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Chermside, Queensland, Australia

[6]Translational Research Institute, Woolloongabba, Queensland, Australia

Keywords: Antibiotic, AMR, gene expression, *Pseudomonas aeruginosa*, efflux pumps, qPCR, *ampC*, genomics

Running title: Assays for rapid AMR detection in *P. aeruginosa*

*These authors contributed equally

Corresponding authors:

Derek Sarovich, dsarovich@usc.edu.au Ph: +61 7 5456 3748

Erin Price, eprice@usc.edu.au Ph: +61 7 5456 5568

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Abstract

The rise of antimicrobial-resistant (AMR) bacteria is a global health emergency. One critical facet in tackling this epidemic is more rapid AMR diagnosis in serious multi-drug resistant pathogens like *Pseudomonas aeruginosa*. Here, we designed and then validated two multiplex quantitative real-time PCR (qPCR) assays to simultaneously detect differential expression of the resistance-nodulation-division efflux pumps MexAB-OprM, MexCD-OprJ, MexEF-OprN, MexXY-OprM, the AmpC β-lactamase, and the porin OprD, which are commonly associated with chromosomally-encoded AMR. Next, qPCRs were tested on 15 sputa from 11 participants with *P. aeruginosa* respiratory infections to determine AMR profiles *in vivo*. We confirm multiplex qPCR testing feasibility directly on sputa, representing a key advancement in *in vivo* AMR diagnosis. Notably, comparison of sputa with their derived isolates grown in Luria-Bertani broth (±2.5% NaCl) or a 5-antibiotic cocktail showed marked expression differences, illustrating the difficulty in replicating *in vivo* expression profiles *in vitro*. Cystic fibrosis sputa showed significantly reduced *mexE* and *mexY* expression when compared with chronic obstructive pulmonary disease sputa, despite harbouring fluoroquinolone- and aminoglycoside-resistant strains, indicating that these loci are not contributing to AMR *in vivo.* *oprD* was also significantly downregulated in cystic fibrosis sputa, even in the absence of contemporaneous carbapenem use, suggesting a common adaptive trait in chronic infections that may affect carbapenem efficacy. Sputum *ampC* expression was highest in participants receiving carbapenems (6.7-15x), some of whom were simultaneously receiving cephalosporins, the latter of which would be rendered ineffective by the upregulated *ampC*. Our qPCR assays provide valuable insights into the *P. aeruginosa* resistome, and their use on clinical specimens will permit timely treatment alterations that will improve patient outcomes and antimicrobial stewardship measures.

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Introduction

The persistent rise in the prevalence and dissemination of antimicrobial-resistant (AMR) bacteria threatens to push humankind towards a post-antibiotic world (1) where untreatable superbugs endanger global health and food security and cause significant morbidity, mortality and economic burden (2). The opportunistic Gram-negative bacterium, *Pseudomonas aeruginosa*, is a member of the 'ESKAPE' group of AMR pathogens that represent the greatest concern to global health (3). *P. aeruginosa* can cause life-threatening infections (4), including in those with chronic respiratory diseases where localised immune defences are compromised such as cystic fibrosis (CF) or chronic obstructive pulmonary disease (COPD) (5). Once infection is established, *P. aeruginosa* eradication is made more difficult by many factors, including its high intrinsic AMR and its capacity to develop multi-drug resistance (MDR) to all classes of clinically-relevant antibiotics (6).

AMR diagnostics are a critical weapon in our battle against superbugs as they enable rapid, cost-effective, and high-throughput AMR detection, leading to more judicious and targeted antibiotic use (7). However, a lack of such diagnostics means that broad-spectrum antimicrobials are commonly used in the clinic in lieu of personalised treatments guided by antimicrobial sensitivity, genotype, and gene expression data (8). This practice, exacerbated during the COVID-19 pandemic (9), has unfortunately contributed to the emergence, persistence, and spread of AMR and MDR pathogens worldwide, with potentially devastating outcomes including treatment failure and mortality (10). Advancements in next-generation sequencing (NGS) technologies are enabling close-to-real-time identification of AMR (11). However, it is currently impractical and costly to use these technologies for rapid, high-throughput detection (12); as such, their implementation in routine clinical diagnostics is not yet feasible. Instead, nucleic acid-based detection platforms such as real-time PCR remain vital – and substantially cheaper, simpler, and more accessible in routine clinical microbiology services than NGS – for the rapid identification of pathogens and their AMR determinants (12). In addition to identifying AMR-conferring single-nucleotide polymorphisms

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

[SNPs] (13, 14), insertions/deletions (15), copy-number variants (16), gene gain (17, 18), or gene loss (19), targeting altered RNA expression of key AMR loci (20-23) provides a rapid way to identify the phenotypic consequences of the myriad genotypic variants that underpin AMR. For example, a quantitative real-time PCR (qPCR) targeting upregulation of three key AMR resistance-nodulation-division (RND) efflux pumps in the melioidosis pathogen, *Burkholderia pseudomallei*, enables the simultaneous identification of meropenem (MEM) resistance, and decreased susceptibility towards doxycycline and co-trimoxazole, in a single reaction (24).

Due to the large number of genetic mutations that can confer AMR in *P. aeruginosa* (25, 26), it remains impractical to target each individual variant using PCR. Fortunately, most clinically-relevant AMR in *P. aeruginosa* is thought to be conferred by a handful of key mechanisms, some of which alter gene expression to drive the AMR phenotype (25). The primary AMR-conferring mutations in *P. aeruginosa* include those that cause: i) *oprD* inactivation or repression, which commonly leads to carbapenem resistance (27, 28); ii) *ampC* hyper-production, a predominant cause of β-lactam AMR (25); iii) DNA gyrase A (*gyrA*) alteration, associated with fluoroquinolone (FQ) AMR (13, 29); and iv) upregulation of one or more RND efflux pumps, leading to AMR or MDR (23). The most important AMR-conferring RND efflux pumps in *P. aeruginosa* are MexAB-OprM (30) (FQs, β-lactams including carbapenems (31), and β-lactam inhibitors (25)), MexEF-OprN (FQs) (32), MexXY (33) (aminoglycosides and FQs (34)), and MexCD-OprJ (35) (FQs (36) and some fourth-generation cephalosporins (37)).

Whilst PCR assays exist to individually detect differential gene expression of *ampC* (20, 26, 34), *mexB* (22, 38), *mexX* (20, 39), *mexY*, *mexD, mexF* (22, 23), *mexA* and *oprD* (22, 34, 39) in *P. aeruginosa*, none simultaneously detect expression of these genes. In addition, nearly all *P. aeruginosa* AMR gene expression studies to date have assessed lab-cultured isolates (23, 38); with only one published study assessing AMR gene expression *in vivo*, whereby singleplex assays were used to detect *ampC*

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

and *mexX* expression in 31 CF sputa, followed by comparison with corresponding derived isolates (20).

To address these knowledge gaps, we developed and validated two multiplex qPCR assays to simultaneously detect altered expression of six key genes that confer AMR towards most clinically-relevant antibiotic classes, using *rpsL* as an internal reference gene for expression normalisation. qPCRs were initially tested in cultures, and subsequently directly on 15 sputa, to permit *in vivo P. aeruginosa* gene expression characterisation (20), thus removing transcriptional biases introduced by culturing. qPCR results were also correlated with current anti-pseudomonal treatment to determine the impact of antibiotic therapy on *in vivo* AMR gene expression, along with strain phenotype and predicted *in silico* AMR genotype data.

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Methods

Ethics statement and participant recruitment. This study was approved by The Prince Charles Hospital (TPCH) Human Research Ethics Committee, project IDs HREC/13/QPCH/127 (CF) and HREC/2019/QPCH/48013 (COPD). Site-specific approvals were obtained for CF recruitment at TPCH, Brisbane, Australia, and COPD recruitment at Sunshine Coast Hospital and Health Service, Sunshine Coast, Australia. CF sputa were collected from participants with chronic *P. aeruginosa* infection who were admitted to the Cystic Fibrosis Centre at TPCH for intravenous antibiotic therapy; COPD sputa was collected from participants either admitted to Sunshine Coast University Hospital (SCUH) for pulmonary exacerbations, or whose symptoms were being managed at home as part of the Respiratory Acute Discharge Service program; whether they had acute or chronic *P. aeruginosa* infection was not known. All participants provided written consent.

Total RNA extraction and microbial RNA enrichment from sputa. Nine sputa from five CF participants, and six sputa from six COPD participants (40) (Table 1), all with high-load *P. aeruginosa* infections according to sputum culture onto MacConkey agar (Oxoid, Heidelberg West, VIC, Australia), were subjected to total RNA extraction to determine *in vivo P. aeruginosa* AMR gene expression profiles. An additional six sputa from *P. aeruginosa*-infected COPD participants with low *P. aeruginosa* load were also examined, along with three COPD sputa and 1 COPD bronchial washing from *P. aeruginosa* culture-negative participants. Sputa were collected directly into RNA stabilisation reagent (10mM EDTA, 25mM sodium citrate, 700g/L ammonium sulphate; pH=5.2; Sigma-Aldrich, Castle Hill, NSW, Australia) to immediately halt transcriptional activity, and kept at 4°C until RNA extraction (up to ~1 month). Between 30 µL and 1 mL sputum was placed into 0.5-6 mL TRI Reagent LS (Sigma) and 30-240 µL 2-mercaptoethanol (Sigma) aliquoted into sterile, RNase-free 2 mL O-ring tubes (SSIBio, Lodi, CA, USA) containing ~100 µL equal mixture of 0.1 and 0.5 mm zirconia beads (Daintree Scientific, St Helens, Tasmania, Australia). Tubes were parafilmed and subjected to four rounds of bead beating at 30 sec pulses using the Minilys tissue homogeniser on the medium setting

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

(Bertin Instruments, Montigny-le-Bretonneux, France), with samples cooled on ice for >30 sec after each round to minimise RNA degradation. Extracted RNA was treated with DNase Max (Qiagen), confirmed DNA-free using a 16S ribosomal RNA gene PCR (41), and host RNA-depleted using MICROBEnrich (Thermo Fisher Scientific, Seventeen Mile Rocks, QLD, Australia) as per manufacturer's instructions. cDNA (iScript; Bio-Rad, Gladesville, NSW, Australia) was qPCR-tested at neat and 1:10 concentrations.

Growth conditions and antibiotic sensitivity testing. Nineteen *P. aeruginosa* strains (12 CF, 7 COPD) were isolated from sputa using MacConkey agar and incubated at 37°C for 24 h. Subcultures were grown on Luria-Bertani (LB) agar (Oxoid) under the same conditions. All strains were confirmed as *P. aeruginosa* by rapid chelex-100 (Bio-Rad) heat soak extraction (42) followed by *ecfX* real-time PCR on a 1:50 dilution of the chelex supernatant (43). Susceptibility towards amikacin (AMK; 30µg), cefepime (30µg), ceftazidime (CAZ; 30µg), ciprofloxacin (5µg), colistin (10µg), imipenem (10µg), piperacillin (30µg), piperacillin-tazobactam (100µg/10µg), polymyxin B (300U), and tobramycin (TOB; 10µg) were determined by disc diffusion (Edwards Group, Murrarie, QLD, Australia); Etests were used for MEM susceptibility testing (bioMérieux, Baulkham Hills, NSW, Australia). Sensitivity, intermediate resistance, and AMR were determined using CLSI M100S-Ed27:2021 guidelines (Table 1). PAO1 (LMG 12228) was included as a wild-type reference. MDR was defined as non-susceptibility to at least one antibiotic in three or more antibiotic classes (44).

Growth experiments and RNA extraction. To assess AMR gene expression levels in derived cultures, a starting inoculum of 10^5 cells was grown to late-log phase (OD_{600}≈1) with orbital shaking at 250 rpm (Ratek Laboratory Equipment [model number OM11], Boronia, VIC, Australia) for 16 h at 37°C in 2mL LB broth ±2.5% NaCl. RNA was extracted using TRI Reagent (Sigma-Aldrich) and treated with TURBO DNase (Thermo Fisher Scientific) according to manufacturer's instructions. 1:10-diluted DNA-free RNA was converted to cDNA using iScript. cDNA was diluted 1:25 in molecular-grade H_2O prior to qPCR.

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

We also attempted to induce AMR gene expression in two *P. aeruginosa* cultures, SCHI0002.S.9 and SCHI0010.S.1, using sub-inhibitory concentrations (0.25µg/mL each) of five antibiotics not used in *P. aeruginosa* treatment but known to induce its RND efflux pumps – gentamicin for *mexX* upregulation (45), novobiocin for *mexB* upregulation (31), norfloxacin for *mexC* upregulation (46), chloramphenicol for *mexE* upregulation (47) and ampicillin for *ampC* upregulation (48). These strains were selected as both encode MDR phenotypes; in addition, SCHI0010.S.1 encodes a high-consequence frameshift mutation in MutS (R360fs), resulting in a hypermutator phenotype (49).

Multiplex AMR locus qPCR assay design and PCR conditions. To quantify *mexAB-oprM*, *mexCD-oprJ*, *mexEF-OprN*, *mexXY-OprM*, *ampC*, and *oprD* expression, two multiplex assays targeting the *mexB, mexC, mexE*, *mexY, ampC*, and *oprD* genes, respectively, were designed (Table 2). A BLAST database comprising 730 *P. aeruginosa* genomes (50-54) was used to identify conserved regions for oligo design. Oligo self-dimers and heterodimers were assessed and avoided as previously described (55). Each PCR consisted of 1× SsoAdvanced Universal Probes Supermix (Bio-Rad), optimised primer and probe concentrations (Macrogen Inc., Geumcheon-gu, Seoul, South Korea; Table 2), 1 µL genomic DNA (gDNA) or cDNA template, and PCR-grade H_2O, to 5 µL. Isolate gDNA/cDNA thermocycling comprised enzyme activation at 95°C for 2 min, followed by a 2-step program (95°C for 5 sec and 60°C for 15 sec) for 45 cycles; for sputum cDNA, a 3-step program (95°C for 5 sec, 60°C for 15 sec, and 72°C for 15 sec) for 45 cycles was used to enhance *P. aeruginosa* detection from polymicrobial DNA.

qPCR assay limits of detection (LoD) and quantification (LoQ). LoD and LoQ values were determined for each assay when in multiplex format using 1:10 serial dilutions of SCHI0005.S.10 *P. aeruginosa* genomic DNA ranging from 40 to 4×10^{-6} ng across eight replicates, as previously described (56, 57). Genome equivalents (GEs) were calculated based on the average PAO1 genome size of 6.22Mbp and a single copy of each gene. For all assays, all samples were run in duplicate, and at least two no-template controls were included in each run.

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

174 **qPCR normalisation and analysis.** The constitutively expressed *rpsL* gene (Table S1) was used to
175 normalise AMR gene expression via the difference in cycles-to-threshold (ΔC_T) method (34, 58). After
176 *rpsL* normalisation, ΔC_T values were further normalised against either PAO1 expression, or to
177 SCHI0070_D2 COPD sputum ($\Delta\Delta C_T$), the latter of which enabled gene expression comparison among
178 sputa, and between sputa and derived isolates. SCHI0070_D2 COPD sputum was chosen for
179 normalisation as this participant had no recent history of anti-pseudomonal antibiotic treatment, its
180 derived isolate, SCHI0070.S.1, was sensitive towards all 11 anti-pseudomonal antibiotics (Table 1),
181 and there was good gene expression across all seven loci for this sample, thus enabling relative
182 expression profiling of qPCR-tested genes across all tested sputa. For AMR loci lacking detectable
183 PCR amplification, a C_T value of 45 was assigned to permit visualisation of genes with very low/no
184 expression. According to previously defined criteria (23), strains were regarded as hyper-producers if
185 their AMR loci exhibited >10-fold higher expression compared with PAO1, except for *mexB* and
186 *mexY,* which were considered hyper-producing if >3-fold higher expression than PAO1 (23, 34, 38).

187 **Strain genome sequencing.** The genomes of 14 strains have been previously published (13); paired-
188 end Illumina genomes for SCHI0065.S.1 and SCHI0070.S.1 were generated in the current study and
189 appended to NCBI BioProject PRJNA761496. We did not sequence SCHI0018.S.11, SCHI0038.S.2, or
190 SCHI0038.S.4 as these data were not considered essential for study outcomes.

191 **Culturome sequencing and *P. aeruginosa* mixture analysis.** Culturomes for SCHI0002_D8,
192 SCHI0002_D329, SCHI0010_D7, SCHI0013_D4, SCHI0038, SCHI0039, and SCHI0050_D3 were
193 generated from Chocolate agar culture sweeps. Microbial cells were lysed with 250 U/mL
194 mutanolysin, 22 U/mL lysostaphin, and 20mg/mL lysozyme, followed by DNA extraction using the
195 Qiagen DNeasy Blood and Tissue kit 'Pretreatment for Gram-Positive Bacteria' protocol. Culturomic
196 data were Illumina paired-end sequenced at the Australian Genome Research Facility (Melbourne,
197 VIC, Australia) or Ramaciotti Centre for Genomics (Sydney, NSW, Australia) to obtain a minimum of 7
198 million reads. The culturomic sequence data are available under NCBI BioProject PRJNA761496.

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

P. aeruginosa mixtures were assessed by mapping reads to PAO1 (GenBank: CP053028.1) with ARDaP v1.9 (59) (https://github.com/dsarov/ARDaP) using the --mixtures flag. Heterogeneous variant sites were then identified and counted from each sample's variant call file (.vcf) based on '0/1' in the 'GT' (genotype) field.

AMR prediction from genomes and culturomes. *In silico* AMR prediction for 16 genome-sequenced isolates, PAO1 (Table 1), and the sputum culturomic data was carried out using the *P. aeruginosa*-specific database in ARDaP. Prior to ARDaP analysis, *Pseudomonas* (taxid: 286) and *P. aeruginosa* (taxid: 287) specific reads were extracted from the raw culturomic data using Kraken 2 (60) to classify reads followed by sektq (https://github.com/lh3/seqtk) for retrieval, with resultant coverage ranging from 21x to 43x (calculated using Mosdepth (61)). For culturomic analysis, ARDaP was again run in mixture mode (--mixtures flag), with the ResFinder (62) component disabled due to the presence of multiple species.

Statistical analysis. Gene expression differences were assessed using a two-way analysis of variance test and Tukey's multiple comparison test using GraphPad Prism (GraphPad Software Inc., CA, USA). Corrected p values of <0.05 were considered significant.

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Results

Multiplex qPCR assay performance. To assess assay sensitivity, LoD and LoQ values were determined using a 10-fold DNA dilution series (40 ng to 0.04 fg). The LoD for all assays was 400 fg (59 GEs), the LoQ for *mexB, mexE* and *mexC* was 400fg (59 GEs), and the LoQ for *rpsL, ampC, mexY* and *oprD* was 4000 fg (587 GEs) (Figures S1 and S2). Based on these results, an *rpsL* C_T<30 was identified as the upper threshold for accurately assessing gene expression of AMR loci.

Antibiotic susceptibility profiles. Testing towards 11 anti-pseudomonal antibiotics identified much higher rates of AMR (range: 0-9 antibiotics) and MDR (10/12 strains) in CF-derived isolates when compared with COPD-derived isolates (range: 0-2 antibiotics; 0/7 MDR strains) (Table 1). This was consistent with much greater antibiotic use in the CF cohort (Table 1) (40). The lowest susceptibility rates were towards cefepime (0% CF and 100% COPD) and piperacillin (33% CF and 100% COPD), whereas all 19 strains were susceptible to colistin and polymyxin B (Table 1). Interestingly, cefepime is rarely used for CF treatment at TPCH, indicating probable cross-resistance towards this antibiotic in all CF-derived isolates. None of the participants were receiving polymyxins; as such, no AMR was expected towards these antibiotics.

***In silico* AMR prediction in isolate genomes.** Genomic analysis of the derived *P. aeruginosa* isolates revealed a much greater number of AMR determinants in the CF-derived strains (Table 1). Although some AMR determinants were identified in COPD isolates, only one was associated with dysregulated expression of the six AMR loci. In contrast, many CF-derived isolates encoded mutations predicted to alter gene expression of our qPCR gene targets (Table 1). Specifically, *ampC* overexpression was predicted in SCHI0030.S.2 and SCHI0030.S.3 due to AmpD regulator loss (P42fs) (63), and a non-inducible *ampC* phenotype was predicted in SCHI0038.S.3 due to a E592fs nonsense mutation in AmpG (64); *mexAB-oprM* overexpression was predicted in SCHI0002.S.9 and SCHI0002.S.12 due to a D187H missense mutation in the NalD regulator (65); and *mexCD-oprJ* overexpression was predicted in SCHI0030.S.4 due to NfxB regulator loss (F126fs) (66). No mutations

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

associated with *mexEF-oprN* or *mexXY-oprM* overexpression were identified. Although not associated with gene expression changes, *oprD* loss was predicted in SCHI0002.S.8 (W339Ter) and SCHI0030.S.3 (G193fs), which is linked to carbapenem resistance, especially when associated with *ampC* upregulation (25, 67) as observed in SCHI0030.S.3.

Other AMR determinants were identified in our strain dataset, including multiple determinants encoding decreased susceptibility or AMR towards CIP (GyrA T83I, D87H or D87N, GyrB S466F and ParE A473V (68)) (Table 1). In addition, an R504C missense variant in FtsI, known to confer resistance to β-lactams (69), was detected in three CF-derived, multi-β-lactam-resistant isolates (SCHI0002.S.8, SCHI0030.S.2, and SCHI0030.S.3), and a FusA1 missense mutation, A555E (70), was identified in CF-derived isolate SCHI0010.S.1 (AMK- and TOB-resistant) (Table 1). Finally, MexEF-OprN loss was predicted in SCHI0013.S.2 and SCHI0013.S.12 due to a frameshift (R229fs) in the MexE membrane fusion protein, and in SCHI0030.S.2 and SCHI0030.S.3 due to the introduction of a stop codon (Y37Ter) in the MexF multidrug inner membrane transporter (71). Unlike the AMR variants, these *mexE* and *mexF* mutations render the MexEF-OprN pump inoperable, and thus unable to contribute towards AMR, irrespective of *mexEF-oprN* upregulation.

***In silico* AMR prediction in culturomes.** Mixed variant site analysis (Table S2) of culturomic data identified multiple *P. aeruginosa* strains in 1/4 CF and 0/3 COPD sputa. The SCHI0002_D8 culturome had a high number of mixed variant sites (21664 variants), confirming that ≥2 genetically distinct strains were present; in contrast, multiple strains were not detected in the SCHI0002_D329, SCHI0010_D7, SCHI0013_D4, SCHI0038, SCHI0039, or SCHI0050_D3 sputa (833, 1521, 701, 1039, 688, 678 variants, respectively) when compared with mixed variant site analysis in clonal, derived strains (Table S2).

ARDaP AMR prediction (Table 1) identified AMR determinants not retrieved during single-strain culturing in 3/7 culturomes (3/4 CF and 0/3 COPD sputa). GyrB E483D (72) and ParC S87W (73), known to contribute to ciprofloxacin resistance, were identified in SCHI0002_D8 at a frequency of

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

8% and 10%, respectively; further, this sample had minor components of the AMR determinants FdnH V215fs (12%), PA1259 F273fs (38%), PA2198 R33fs (11%), and PepA E363fs (14%), all of which cause decreased piperacillin susceptibility (74). A FtsI H394R missense mutation (75) was identified in SCHI0010 at 61% prevalence, and in SCHI0013, a W6Ter nonsense mutation caused by a G→A transition was identified in OprD at 22% prevalence, predicted to cause carbapenem resistance, along with PA3093 loss (15%), associated with intermediate piperacillin resistance (Table 1). Importantly, no additional mutations were identified that were predicted to alter expression of the six AMR loci. Further, the culturomic data did not detect some AMR determinants found in the single-isolate data (Table 1).

Comparison of AMR variant prediction with *in vitro* AMR gene expression. Relative AMR gene expression in derived *P. isolates* grown in LB broth (*n*=15; Figure S3), LB+NaCl (*n*=14; Figure S4), or a 5-antibiotic cocktail (*n*=2; Figure S5) was assessed. All qPCR targets exhibited expression in at least one strain; however, in some strains, particularly the CF-derived isolates, certain genes exhibited no expression (Figures S3-S5). Just two loci were expressed in all tested strains across all conditions: the housekeeping gene *rpsL* (C_T=25.3±1.97) and *mexB* (C_T=29.0±2.14). *oprD* was expressed in all strains except SCHI0039.S.1 grown in LB+NaCl. In contrast, *ampC*, and *mexC*, *mexE*, and *mexY* were expressed in 1, 23, 26, and 2 of the 31 tested strains, respectively. Genetic analysis of all qPCR-targeted loci confirmed 100% primer and probe matches in those strains with genomic data, thereby ruling out assay failure as a cause of undetectable expression.

Unexpectedly, there was no concordance between *in silico* AMR predictions and qPCR results for strains grown under any of the tested conditions. SCHI0030.S.2 and SCHI0030.S.3, which were predicted to upregulate *ampC* through a previously undocumented AmpD frameshift variant (P42fs), exhibited negligible or no *ampC* expression when grown in LB broth or LB+NaCl (Figures S3 and S4). In contrast, SCHI0010.S.1, which does not encode any known chromosomal variant associated with *ampC* upregulation (Table 1), demonstrated *ampC* hyper-expression (43x) in LB broth relative to

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

289 PAO1, although no detectable *ampC* expression under salt (Figure S2) or antibiotic stress (Figure S3).
290 Similarly, SCHI0002.S.9 and SCHI0002.S.12 failed to overexpress *mexB*, and, surprisingly,
291 SCHI0030.S.4 failed to overexpress *mexC*, despite predicted upregulation. Once again, SCHI0010.S.1
292 grown in LB, but not in LB+NaCl, unexpectedly hyper-expressed *mexB* (19x), *mexC* (19x), *mexE* (24x),
293 and *mexY* (16x) in lieu of encoding any known variants associated with upregulation of these loci. No
294 other strain tested under any condition upregulated *mexB*, *mexC*, *mexE*, or *mexY*. Although no
295 strains were predicted to exhibit *oprD* downregulation, *oprD* was not expressed in SCHI0039.S.1
296 grown in LB±NaCl, and was significantly downregulated in SCHI0010.S.1 grown in LB+NaCl (Figures S3
297 and S4). All other strains exhibited good *oprD* expression, including SCHI0002.S.8 and SCHI0030.S.3;
298 although these strains encode truncated OprD, these deleterious mutations occur downstream of
299 the oligo-binding sites, and are therefore undetected by our assay.

300 **AMR gene expression in sputa.** All COPD sputa yielded more similar expression profiles to the
301 SCHI0070_D2 COPD control than any of the nine CF sputa (Figure 1). The only overexpressed loci in
302 the CF or COPD sputa were: *ampC* (4/9 CF [1.7-15.1x] and 2/5 COPD [1.7-3.5x]), *mexB* (3/5 COPD
303 [1.5-2.5x]), *mexC* (2/9 CF [1.7-2.1x] and 2/5 COPD [6.4x each]), *mexY* (4/5 COPD [1.8-7.3x]), and *oprD*
304 (3/5 COPD [1.7-51x]) (Figure 2). All CF sputa exhibited downregulation or no expression of *mexB*
305 (≥4.0x), *mexE* (≥3.9x), *mexY* (≥5.2x), and *oprD* (≥377x), and 6/9 were downregulated or had no
306 detectable expression for *mexC* (≥3.4x). When comparing CF and COPD sputum expression, no
307 significant difference was observed for *ampC*, *mexB*, or *mexC*; in contrast, *mexE*, *mexY*, and *oprD*
308 were all significantly downregulated in CF sputa (Figure 1).

309 Correlation of qPCR results with antibiotic treatment (Table 1) identified that sputum *ampC*
310 expression levels were a good indicator of current β-lactam use, with 4/5 sputa with elevated *ampC*
311 expression collected from participants contemporaneously receiving β-lactams (SCHI0002_D8,
312 SCHI0010_D7, SCHI0013_D4, and SCHI0018_D8). Notably, 2/3 sputa (SCHI0002_D8 and
313 SCHI0013_D4) obtained from participants being treated with MEM, either with or without CAZ,

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

overexpressed *ampC* at high levels (6.7-15x); in contrast, *ampC* expression was only moderately upregulated (1.7-1.9x) in two sputa (SCHI0010_D7 and SCHI0018_D8) from participants on CAZ but not MEM (Table 1; Figure 2). *ampC* was downregulated or not expressed in eight sputa (Figure 2) - of these, four were collected from participants receiving no antibiotics at the time of collection, three were receiving antibiotics other than β-lactams, and just one (SCHI0002_D329) was receiving CAZ and MEM at the time of sputum collection (Table 1).

AMR gene expression between sputa and *in vitro* cultures. Sputum AMR gene expression was compared with derived cultures grown in LB broth (Figure S3), LB+NaCl (Figure S4), and a 5-antibiotic cocktail (Figure S5) to determine whether culture AMR gene expression was reflective of *in vivo* conditions. Overall, there was very poor concordance between *in vivo* and *in vitro* expression profiles across all tested *in vitro* conditions, with most loci exhibiting dissimilar expression between derived isolates and their corresponding sputa. Most striking was *oprD*, which, in most cases, was upregulated in strains grown under the three *in vitro* conditions (Figures S3-S5) yet largely downregulated *in vivo* (Figure 2).

RND efflux pump expression during antibiotic treatment. The four longitudinal sputa collected from SCHI0030, who received intravenous TOB and aztreonam for 15 days, provides an interesting case study for observing AMR gene expression dynamics before, during, and after antibiotic treatment (Table 1). Although TOB has previously been shown to induce MexXY-OprM expression in CF sputa (20), we unexpectedly did not observe AMR gene expression changes in SCHI0030 sputa (Figure 2). Five sputa from other CF participants also showed limited or no *mexY* expression. In comparison, *mexY* was significantly upregulated in 4/5 COPD sputa (Figure 2), none of whom have ever received TOB (Table 1).

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Discussion

Here, we developed and validated two multiplex qPCR assays for the simultaneous detection of altered AMR locus expression in the ESKAPE pathogen, *P. aeruginosa*. When run in multiplex format, our qPCRs showed very good to excellent LoD and LoQ values. qPCRs can be used both on *P. aeruginosa* cultures and directly on human RNA-depleted sputa, the latter of which provides *in vivo* expression profiling that overcomes transcriptional bias introduced with *in vitro* culture (20). Building upon the pioneering work of Martin and colleagues, who first reported limited correlation in *ampC* and *mexX* expression between sputa and corresponding derived isolates (20), we also observed poor concordance between *in vivo* and *in vitro* expression profiles across six tested AMR loci. Further, we found surprisingly poor correlation between *in silico*-predicted and *in vitro* AMR gene expression. These findings raise questions about the clinical utility of *in vitro* antimicrobial gene expression profiling and highlight the need for more work in this critical area of AMR research.

AmpC-driven AMR. We found that sputum *ampC* expression correlated well with contemporaneous β-lactam treatment. In particular, two CF participants (SCHI0010 and SCHI0018) receiving CAZ but no other β-lactams overexpressed *ampC* at moderate levels (1.7-2x); this overexpression increased to 6.7-15x in two other participants (SCHI0002 and SCHI0013) receiving MEM (Table 1; Figure 2). Carbapenems such as MEM can be potent *ampC* inducers (67) and can remain effective even when *ampC* expression is elevated (25), whereas cephalosporins such as CAZ are relatively weak inducers of *ampC* and are readily hydrolysed by this enzyme (25). Our findings confirm that MEM can act as a strong inducer of *ampC* expression *in vivo*. In light of this, we recommend that *P. aeruginosa* infections should not simultaneously be treated with carbapenems and cephalosporins due to potential *ampC* induction, which would render cephalosporin (and likely other β-lactam) antibiotics ineffective (25). In contrast, eight sputa exhibited downregulated or no *ampC* expression (Figure 2), seven of which were taken from participants either not on antibiotics or not receiving β-lactams at the time of sample collection, which likely explains the lack of β-lactam-driven *ampC* selection

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

361 pressure. Of note, two COPD sputa, SCHI0109 and SCHI0050_D3, showed *ampC* upregulation (1.7-
362 3.5x), despite neither participant receiving contemporaneous β-lactam therapy. Whilst the basis for
363 this upregulation is unknown, we speculate that β-lactam use in these participants would be
364 ineffective for *P. aeruginosa* eradication. Taken together, our results demonstrate that routine *ampC*
365 qPCR testing of *P. aeruginosa*-positive specimens is a useful diagnostic for monitoring *in vivo*
366 cephalosporin efficacy, enabling more rapid treatment shifts in instances where *ampC* is
367 upregulated.

368 Unlike sputa, almost all derived isolates failed to express *ampC* when grown in three different liquid
369 media. The exception was the derived isolate from CF participant SCHI0010. In LB broth,
370 SCHI0010.S.1 exhibited *ampC* hyper-expression (15x relative to SCHI0070_D2, and 43x relative to
371 PAO1; Figure S3), yet the corresponding sputum showed only modest *ampC* upregulation (1.7x;
372 Figure 2). This finding was unexpected as SCHI0010.S.1 does not encode any known chromosomal
373 variant associated with *ampC* upregulation (Table 1), and did not overexpress *ampC* when grown in
374 LB+NaCl or the 5-antibiotic cocktail (Figures S4-S5). These results indicate that SCHI0010.S.1 encodes
375 an enigmatic determinant for upregulating *ampC* expression when grown under particular
376 conditions. Whilst the basis of this overexpression requires further investigation, we postulate that it
377 may be driven by global transcriptional regulator inactivation due to its hypermutator status,
378 resulting in marked transcriptome differences affecting multiple gene pathways. In contrast, strains
379 SCHI0030.S.2 and SCHI0030.S.3, both predicted to upregulate *ampC* due to a truncated AmpD,
380 exhibited negligible or no *ampC* expression *in vitro* (Figures S3-S4). This result correlated with the
381 longitudinal SCHI0030 sputa, all of which exhibited significantly downregulated *ampC* expression.
382 One possibility for the lack of *ampC* expression in SCHI0030 is that the AmpD P42fs mutation may
383 only confer a partially de-repressed *ampC* phenotype (26); another possibility is that additional
384 chromosomal determinants, such as those occurring in other AmpD homologues (26) or DacB (76),
385 may be required to confer *ampC* upregulation (63) in AmpD P42fs-encoding strains.

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

386 Expression of *ampC* was also undetectable in the MDR strain, SCHI0002.S.9, across the three *in vitro*
387 conditions (Figures S3-S4). Whilst this observation is consistent with the lack of predicted *ampC*
388 dysregulation in the SCHI0002.S.9 genome, it does not reflect the AMR phenotype of this strain,
389 which was resistant to all six tested penicillin, cephalosporin, and carbapenem antibiotics (Table 1).
390 In addition, the corresponding SCHI0002_D8 sputum displayed the greatest *ampC* upregulation (15x;
391 Figure 2), probably due to contemporaneous CAZ and MEM treatment (Table 1). One possible
392 explanation for these spurious results is that high sputum *ampC* levels are conferred by an un-
393 retrieved *P. aeruginosa* strain (20), as supported by two distinct AMR phenotypes and genotypes
394 isolated from SCHI0002_D8, SCHI0013_D4, and SCHI0030_D50 sputa (Table 1) and *in silico* strain
395 mixture analysis of culturomic data, which identified multiple *P. aeruginosa* strains in one CF sputum
396 sample (SCHI0002_D8) (Table S2). Indeed, phenotypic and genotypic diversity of *P. aeruginosa* is
397 well-documented in chronic CF infections (77), and increasingly, in COPD infections (78). However,
398 our culturomic mixture analysis failed to identify any additional mutations associated with altered
399 gene expression of *ampC* or the other tested AMR loci (Table 1), so it remains unconfirmed whether
400 undetected determinants are contributing to AMR. Another explanation is that *ampC* expression in
401 SCHI0002 strains may require MEM (20) or cefoxitin (79) rather than ampicillin (48) for *in vitro*
402 induction, as certain antibiotics are known to be better than others for inducing *ampC* (20).
403 However, antibiotic induction only provides a crude representation of *in vivo P. aeruginosa* activity,
404 as the lung environment is exceptionally difficult to mimic *in vitro* (20, 77, 80). The lack of correlation
405 between *ampC* upregulation in sputa and derived cultures (Figures S3-S5) has also been reported in
406 a separate study (20), and emphasises the challenges in replicating *in vivo* conditions *in vitro*.

407 **Efflux-mediated AMR.** *mexB*, *mexC*, *mexE* and *mexY* represent the RND efflux pumps most
408 frequently associated with AMR and MDR in *P. aeruginosa* (23, 25). As most CF participants were
409 being treated with anti-pseudomonal antibiotics at the time of sputum collection, and many of their
410 derived isolates encode key mutations associated with altered RND efflux pump expression (Table
411 1), we expected upregulation of these four efflux pumps in CF sputa. It was therefore surprising that

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

mexC was the only efflux system that demonstrated modest (1.7-2.1x) upregulation in a few patients (2/9 CF sputa), whereas the other RND efflux systems were largely downregulated, or switched off entirely, in CF sputa (Figure 2). Also surprising was that most COPD sputa showed good expression of these loci, despite only two COPD participants contemporaneously receiving anti-pseudomonal antibiotics, and almost no AMR phenotypes or efflux pump expression-altering genotypes in the derived COPD isolates (Table 1). This difference between diseases was most apparent for *mexE*, *mexY*, and *oprD*, which were significantly downregulated in CF but not COPD sputa (Figure 1). Although our dataset is small, these observations suggest that RND efflux pump expression, and particularly *mexE* and *mexY* expression, may not be required for chronic *P. aeruginosa* persistence in CF airways. This finding contradicts prior *in vitro* work suggesting that MexXY-OprM efflux pump upregulation is necessary for *P. aeruginosa* survival in the CF lung (81). We further postulate that the MexEF-OprN and MexXY-OprM RND efflux pumps may have a minimal role, if any, in conferring AMR in *P. aeruginosa in vivo*. *mexE* and *mexY* qPCR testing across a larger CF and COPD sputum panel is needed to determine to veracity of our findings.

One possible explanation for efflux pump downregulation in CF sputa is that the CF cohort all harboured chronic *P. aeruginosa* infections, whereas the COPD cohort potentially only had transient (i.e. acute) infections. Like virulence factors (82), RND efflux pump expression may be upregulated during the acute phase but then downregulated once *P. aeruginosa* transitions to a chronic lifestyle, the latter of which is characterised by biofilm formation and reduced metabolic activity (25, 83). In support of this hypothesis, longitudinal sputa collected from CF participant SCHI0030 just prior, during, and after a 15-day course of intravenous TOB and aztreonam treatment showed virtually no change in RND efflux pump expression, with all AMR genes (including *mexY*) downregulated (Figure 2) despite the aminoglycoside onslaught. In addition, one of two SCHI0030 strains obtained 35 days after antibiotic cessation was fully susceptible to all 11 tested antibiotics, including TOB, hinting at insufficient antibiotic penetration due to biofilm. As ours is one of the few studies to investigate *P. aeruginosa* AMR gene expression *in vivo*, and the first to assess COPD sputa, more work is required

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

to verify these hypotheses, as there remains stark limitations in our understanding of the characteristics of *P. aeruginosa* infection (including AMR development), particularly in people with COPD (84). Examining *in vivo* AMR gene expression dynamics over a long-term *P. aeruginosa* infection would shed important information about the adaptive processes that occur during the transition from acute infection to chronic persistence. We anticipate that our multiplex assays will be a valuable tool for such studies.

Analysis of RND efflux expression among the CF-derived isolates encoding predicted RND efflux upregulation revealed that almost none demonstrated increased efflux pump expression *in vitro* (Figures S3-S5). Curiously, the MDR and hypermutated isolate SCHI0010.S.1, which does not encode any known mutations associated with RND efflux pump upregulation, exhibited *mexB* (5.3x), *mexC* (1.7x), *mexE* (1.5x), and *mexY* (28x) overexpression when grown in LB, although not when grown in LB+NaCl or the 5-antibiotic cocktail (Figures S3-S5). These results indicate that there are growth-specific requirements associated with upregulation of these genes. Furthermore, these observations collectively indicate that *in vitro* efflux pump expression is not a good proxy for AMR phenotype, as our CF-derived *P. aeruginosa* isolates demonstrate extensive MDR, yet we were unable to reproduce their expected gene expression alterations *in vitro*. Our results contradict other *in vitro* experiments reporting RND efflux pump hyper-expression as a major contributing factor to AMR development in CF airway-derived *P. aeruginosa* (34, 39). Caution should thus be taken when attempting to correlate predicted AMR phenotypes with *in vitro* RND efflux pump expression profiles due to considerable AMR gene expression changes exhibited under different culture conditions.

OprD-mediated AMR. As with the other AMR loci, we saw an unexpectedly poor correlation between *in vitro* and *in vivo oprD* expression. Whereas 17/19 *in vitro* cultures expressed *oprD* at high levels (Figures S3-S5), 9/9 CF and 2/5 COPD sputa exhibited no detectable *oprD* expression (Figure 2), and *oprD* was significantly downregulated in CF sputa (Figure 1). This finding strongly suggests that *oprD* downregulation is a common, and potentially dominant, adaptive *in vivo* trait in chronic *P.*

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

aeruginosa infections. Another noteworthy observation is that *in vivo oprD* downregulation was not strictly associated with contemporaneous carbapenem use, as only three of the CF sputa were obtained during carbapenem treatment, and none of the COPD participants had ever received carbapenems. We posit that this adaptive mechanism may provide a rapid, efficient, and effective way for *P. aeruginosa* to evade carbapenems in lieu of encoding functional *oprD* loss. In support of this hypothesis, two prior studies reported decreased *oprD* expression as a cause of carbapenem AMR in 19/33 (58%) (85) and 39/117 (33%) (86) clinical isolates. However, another study showed that *in vitro oprD* downregulation in carbapenem-resistant isolates is a rare event, occurring in just 5/40 (13%) isolates (34). As our study illustrates, the markedly different *oprD* expression profiles observed among studies may reflect differing *in vitro* growth conditions; nevertheless, these *in vitro* findings show that *P. aeruginosa* can modulate its *oprD* expression to confer carbapenem AMR. Like *ampC*, our *oprD* results indicate that there may be great clinical value in characterising *in vivo oprD* expression to rapidly identify *P. aeruginosa* infections that are recalcitrant to carbapenem therapy.

Concluding remarks. Our results add further weight to growing concerns about the relevance of *in vitro* AMR research, particularly *in vitro* gene expression analysis, in clinical practice (87, 88). Due to poor correlation between *in vitro* AMR testing and treatment outcomes in CF, empirical antibiotic selection remains the preferred option due to better patient responses (80). Our findings confirm that alternative approaches must be explored that minimise the transcriptional biases introduced during culture (89) to better reflect *in vivo P. aeruginosa* gene expression (87). We recommend that, wherever possible, gene expression of clinical specimens (e.g. sputum) be tested alongside cultured isolates (20). This information will greatly improve our understanding of the shortcomings of *in vitro* AMR testing whilst aiding in clinical decision making, providing more targeted treatment strategies, enhancing antimicrobial stewardship, and improving patient outcomes. Finally, implementation of microbial-enriched metagenomic sequencing of clinical specimens and *in silico* mixture analysis would permit the detection of AMR determinants within a heterogeneous strain population,

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

488 providing a superior method to culture-based methods for comprehensive AMR determinant

489 identification.

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Acknowledgements

This work was supported by Advance Queensland (awards AQIRF0362018 and AQRF13016-17RD2), an Australian Government Research Training Program Scholarship, the Wishlist Sunshine Coast Health Foundation (award 2019-14), the IMPACT Philanthropy Application Program (IPAP2016/01112), UQ-QIMRB (Australian Infectious Disease Grant initiative), the National Health and Medical Research Council (award 455919), The Children's Health Foundation Queensland (50 0 07), and The Health Innovation, Investment and Research Office of Queensland Health. The funders had no role in study design, data acquisition, analysis, interpretation, writing or submission of the manuscript.

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

References

1. Alanis AJ. 2005. Resistance to antibiotics: Are we in the post-antibiotic era? *Arch Med Res* 36:697-705.
2. Zhen X, Lundborg CS, Sun X, Hu X, Dong H. 2019. Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review. *Antimicrob Resist Infect Control* 8:137.
3. Mulani MS, Kamble EE, Kumkar SN, Tawre MS, Pardesi KR. 2019. Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: A review. *Front Microbiol* 10:539-539.
4. Bassetti M, Vena A, Croxatto A, Righi E, Guery B. 2018. How to manage *Pseudomonas aeruginosa* infections. *Drugs Context* 7:1-18.
5. Botelho J, Grosso F, Peixe L. 2019. Antibiotic resistance in *Pseudomonas aeruginosa* - Mechanisms, epidemiology and evolution. *Drug Resist Updat* 44:26-47.
6. Breidenstein EB, de la Fuente-Nunez C, Hancock RE. 2011. *Pseudomonas aeruginosa*: all roads lead to resistance. *Trends Microbiol* 19:419-26.
7. Shallcross LJ, Howard SJ, Fowler T, Davies SC. 2015. Tackling the threat of antimicrobial resistance: From policy to sustainable action. *Philos Trans R Soc Lond B Biol Sci* 370:1-5.
8. O'Neill J. 2014. Antimicrobial resistance: Tackling a crisis for the health and wealth of nations. Accessed 12 August 2021.
9. Patel A. 2021. Tackling antimicrobial resistance in the shadow of COVID-19. *mBio* 12:1-4.
10. Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N, Vlieghe E, Hara GL, Gould IM, Goossens H, Greko C, So AD, Bigdeli M, Tomson G, Woodhouse W, Ombaka E, Peralta AQ, Qamar FN, Mir F, Kariuki S, Bhutta ZA, Coates A, Bergstrom R, Wright GD, Brown ED, Cars O. 2013. Antibiotic resistance - the need for global solutions. *Lancet Infect Dis* 13:1057-1098.
11. Su M, Satola SW, Read TD. 2019. Genome-based prediction of bacterial antibiotic resistance. *J Clin Microbiol* 57:1-15.
12. Rossen JWA, Friedrich AW, Moran-Gilad J. 2018. Practical issues in implementing whole-genome-sequencing in routine diagnostic microbiology. *Clin Microbiol Infect* 24:355-360.
13. Madden DE, McCarthy KL, Bell SC, Olagoke O, Baird T, Neill J, Ramsay KA, Kidd TJ, Stewart AG, Subedi S, Choong K, Fraser TA, Sarovich DS, Price EP. 2021. Rapid fluoroquinolone resistance detection in *Pseudomonas aeruginosa* using mismatch amplification mutation assay-based real-time PCR. *medRxiv*.
14. Richardot C, Plesiat P, Fournier D, Monlezun L, Broutin I, Llanes C. 2015. Carbapenem resistance in cystic fibrosis strains of *Pseudomonas aeruginosa* as a result of amino acid substitutions in porin OprD. *Int J Antimicrob Agents* 45:529-32.
15. Godfroid M, Dagan T, Merker M, Kohl TA, Diel R, Maurer FP, Niemann S, Kupczok A. 2020. Insertion and deletion evolution reflects antibiotics selection pressure in a *Mycobacterium tuberculosis* outbreak. *PLoS Pathog* 16:1-24.
16. Huang TW, Chen TL, Chen YT, Lauderdale TL, Liao TL, Lee YT, Chen CP, Liu YM, Lin AC, Chang YH, Wu KM, Kirby R, Lai JF, Tan MC, Siu LK, Chang CM, Fung CP, Tsai SF. 2013. Copy number change of the NDM-1 sequence in a multidrug-resistant *Klebsiella pneumoniae* clinical isolate. *PLoS One* 8:1-12.
17. Chalhoub H, Sáenz Y, Rodriguez-Villalobos H, Denis O, Kahl BC, Tulkens PM, Van Bambeke F. 2016. High-level resistance to meropenem in clinical isolates of *Pseudomonas aeruginosa* in the absence of carbapenemases: role of active efflux and porin alterations. *Int J Antimicrob Agents* 48:740-743.
18. Stewart AG, Price EP, Schabacker K, Birikmen M, Harris PNA, Choong K, Subedi S, Sarovich DS. 2021. Molecular epidemiology of third-generation cephalosporin-resistant *Enterobacteriaceae* in Southeast Queensland, Australia. *Antimicrob Agents Chemother* 65:1-13.

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

19. Chantratita N, Rholl DA, Sim B, Wuthiekanun V, Limmathurotsakul D, Amornchai P, Thanwisai A, Chua HH, Ooi WF, Holden MT, Day NP, Tan P, Schweizer HP, Peacock SJ. 2011. Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in *Burkholderia pseudomallei*. *Proc Natl Acad Sci U S A* 108:17165-70.
20. Martin LW, Robson CL, Watts AM, Gray AR, Wainwright CE, Bell SC, Ramsay KA, Kidd TJ, Reid DW, Brockway B, Lamont IL. 2018. Expression of *Pseudomonas aeruginosa* antibiotic resistance genes varies greatly during infections in cystic fibrosis patients. *Antimicrob Agents Chemother* 62:1-11.
21. Wheatley R, Diaz Caballero J, Kapel N, de Winter FHR, Jangir P, Quinn A, del Barrio-Tofiño E, López-Causapé C, Hedge J, Torrens G, Van der Schalk T, Xavier BB, Fernández-Cuenca F, Arenzana A, Recanatini C, Timbermont L, Sifakis F, Ruzin A, Ali O, Lammens C, Goossens H, Kluytmans J, Kumar-Singh S, Oliver A, Malhotra-Kumar S, MacLean C. 2021. Rapid evolution and host immunity drive the rise and fall of carbapenem resistance during an acute *Pseudomonas aeruginosa* infection. *Nat Commun* 12:1-12.
22. Lee JY, Ko KS. 2012. OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-beta-lactamases in carbapenem-resistant *Pseudomonas aeruginosa* isolates from South Korea. *Int J Antimicrob Agents* 40:168-72.
23. Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodriguez C, Moya B, Zamorano L, Suarez C, Pena C, Martinez-Martinez L, Oliver A. 2011. Overexpression of *AmpC* and efflux pumps in *Pseudomonas aeruginosa* isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. *Antimicrob Agents Chemother* 55:1906-11.
24. Webb JR, Price EP, Somprasong N, Schweizer HP, Baird RW, Currie BJ, Sarovich DS. 2018. Development and validation of a triplex quantitative real-time PCR assay to detect efflux pump-mediated antibiotic resistance in *Burkholderia pseudomallei*. *Future Microbiol* 12:1403-1418.
25. Poole K. 2011. *Pseudomonas aeruginosa:* Resistance to the max. *Front Microbiol* 2:1-13.
26. Juan C, Moya B, Perez JL, Oliver A. 2006. Stepwise upregulation of the *Pseudomonas aeruginosa* chromosomal cephalosporinase conferring high-level beta-lactam resistance involves three AmpD homologues. *Antimicrob Agents Chemother* 50:1780-7.
27. Shu JC, Kuo AJ, Su LH, Liu TP, Lee MH, Su IN, Wu TL. 2017. Development of carbapenem resistance in *Pseudomonas aeruginosa* is associated with OprD polymorphisms, particularly the amino acid substitution at codon 170. *J Antimicrob Chemother* 72:2489-2495.
28. Sherrard LJ, Wee BA, Duplancic C, Ramsay KA, Dave KA, Ballard E, Wainwright CE, Grimwood K, Sidjabat HE, Whiley DM, Beatson SA, Kidd TJ, Bell SC. 2021. Emergence and impact of *oprD* mutations in *Pseudomonas aeruginosa* strains in cystic fibrosis. *J Cyst Fibros* 21:1-9.
29. Lee JK, Lee YS, Park YK, Kim BS. 2005. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of *Pseudomonas aeruginosa*. *Int J Antimicrob Agents* 25:290-5.
30. Poole K, Tetro K, Zhao Q, Neshat S, Heinrichs DE, Bianco N. 1996. Expression of the multidrug resistance operon mexA-mexB-oprM in *Pseudomonas aeruginosa*: mexR encodes a regulator of operon expression. *Antimicrob Agents Chemother* 40:2021-8.
31. Chen W, Wang D, Zhou W, Sang H, Liu X, Ge Z, Zhang J, Lan L, Yang CG, Chen H. 2016. Novobiocin binding to NalD induces the expression of the MexAB-OprM pump in *Pseudomonas aeruginosa*. *Mol Microbiol* 100:749-58.
32. Köhler T, Epp SF, Curty LK, Pechère JC. 1999. Characterization of MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of *Pseudomonas aeruginosa*. *J Bacteriol* 181:6300-5.
33. Morita Y, Tomida J, Kawamura Y. 2012. MexXY multidrug efflux system of *Pseudomonas aeruginosa*. *Front Microbiol* 3:1-13.
34. Aghazadeh M, Hojabri Z, Mahdian R, Nahaei MR, Rahmati M, Hojabri T, Pirzadeh T, Pajand O. 2014. Role of efflux pumps: MexAB-OprM and MexXY(-OprA), AmpC cephalosporinase and

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

OprD porin in non-metallo-beta-lactamase producing *Pseudomonas aeruginosa* isolated from cystic fibrosis and burn patients. *Infect Genet Evol* 24:187-92.

35. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ, Nishino T. 1996. Overexpression of the *mexC-mexD-oprJ* efflux operon in *nfxB*-type multidrug-resistant strains of *Pseudomonas aeruginosa*. *Mol Microbiol* 21:713-24.
36. Fraud S, Campigotto AJ, Chen Z, Poole K. 2008. MexCD-OprJ multidrug efflux system of *Pseudomonas aeruginosa:* Involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor. *Antimicrob Agents Chemother* 52:4478-4482.
37. Gotoh N, Tsujimoto H, Tsuda M, Okamoto K, Nomura A, Wada T, Nakahashi M, Nishino T. 1998. Characterization of the MexC-MexD-OprJ Multidrug Efflux System in mexA-mexB-oprM Mutants of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 42:1938-1943.
38. Oh H, Stenhoff J, Jalal S, Wretlind B. 2003. Role of efflux pumps and mutations in genes for topoisomerases II and IV in fluoroquinolone-resistant *Pseudomonas aeruginosa* strains. *Microb Drug Resist* 9:323-8.
39. Islam S, Jalal S, Wretlind B. 2004. Expression of the MexXY efflux pump in amikacin-resistant isolates of *Pseudomonas aeruginosa*. *Clin Microbiol Infect* 10:877-83.
40. Webb KA, Olagoke O, Baird T, Neill J, Pham A, Wells TJ, Ramsay KA, Bell SC, Sarovich DS, Price EP. 2021. Genomic diversity and antimicrobial resistance of *Prevotella* spp. isolated from chronic lung disease airways. *Microb Genom* 8:000754.
41. Nadkarni MA, Martin FE, Jacques NA, Hunter N. 2002. Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. *Microbiology (Reading)* 148:257-266.
42. de Lamballerie X, Zandotti C, Vignoli C, Bollet C, de Micco P. 1992. A one-step microbial DNA extraction method using "Chelex 100" suitable for gene amplification. *Res Microbiol* 143:785-90.
43. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP. 2009. Identification of Pseudomonas aeruginosa by a duplex real-time polymerase chain reaction assay targeting the ecfX and the gyrB genes. *Diagn Microbiol Infect Dis* 63:127-31.
44. Horcajada JP, Montero M, Oliver A, Sorlí L, Luque S, Gómez-Zorrilla S, Benito N, Grau S. 2019. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant *Pseudomonas aeruginosa* infections. *Clin Microbiol Rev* 32:1-52.
45. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. 2000. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 44:3322-7.
46. Buffet-Bataillon S, Tattevin P, Maillard J-Y, Bonnaure-Mallet M, Jolivet-Gougeon A. 2016. Efflux pump induction by quaternary ammonium compounds and fluoroquinolone resistance in bacteria. *Future Microbiol* 11:81-92.
47. Fetar H, Gilmour C, Klinoski R, Daigle DM, Dean CR, Poole K. 2011. mexEF-oprN multidrug efflux operon of *Pseudomonas aeruginosa:* Regulation by the MexT activator in response to nitrosative stress and chloramphenicol. *Antimicrob Agents Chemother* 55:508-514.
48. Dunne WM, Jr., Hardin DJ. 2005. Use of several inducer and substrate antibiotic combinations in a disk approximation assay format to screen for AmpC induction in patient isolates of *Pseudomonas aeruginosa*, *Enterobacter* spp., *Citrobacter* spp., and *Serratia* spp. *J of Clin Microbiol* 43:5945-5949.
49. Oliver A, Baquero F, Blázquez J. 2002. The mismatch repair system (*mutS*, *mutL* and *uvrD* genes) in *Pseudomonas aeruginosa*: Molecular characterization of naturally occurring mutants. *Mol Microbiol* 43:1641-1650.
50. van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras J-B, Barbu EM, Shortridge D, Blanc B, Hannum G, Zambardi G, Miller K, Enright MC, Mugnier N, Brami D, Schicklin S, Felderman M, Schwartz AS, Richardson TH, Peterson TC, Hubby B, Cady KC. 2015. Phylogenetic

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

distribution of CRISPR-Cas systems in antibiotic-resistant *Pseudomonas aeruginosa*. *mBio* 6:1-13.

51. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MÁ, Zamorano L, Juan C, Tubau F, Rodríguez C, Moyà B, Peña C, Martínez-Martínez L, Plesiat P, Oliver A. 2016. Deciphering the resistome of the widespread *Pseudomonas aeruginosa* sequence type 175 international high-risk clone through whole-genome sequencing. *Antimicrob Agents Chemother* 60:7415-7423.
52. Kos VN, Déraspe M, McLaughlin RE, Whiteaker JD, Roy PH, Alm RA, Corbeil J, Gardner H. 2015. The resistome of *Pseudomonas aeruginosa* in relationship to phenotypic susceptibility. *Antimicrob Agents Chemother* 59:427-436.
53. Del Barrio-Tofiño E, López-Causapé C, Cabot G, Rivera A, Benito N, Segura C, Montero MM, Sorlí L, Tubau F, Gómez-Zorrilla S, Tormo N, Durá-Navarro R, Viedma E, Resino-Foz E, Fernández-Martínez M, González-Rico C, Alejo-Cancho I, Martínez JA, Labayru-Echverria C, Dueñas C, Ayestarán I, Zamorano L, Martinez-Martinez L, Horcajada JP, Oliver A. 2017. Genomics and susceptibility profiles of extensively drug-resistant *Pseudomonas aeruginosa* isolates from Spain. *Antimicrob Agents Chemother* 61:1-13.
54. Sherrard LJ, Tai AS, Wee BA, Ramsay KA, Kidd TJ, Ben Zakour NL, Whiley DM, Beatson SA, Bell SC. 2017. Within-host whole genome analysis of an antibiotic resistant *Pseudomonas aeruginosa* strain sub-type in cystic fibrosis. *PLoS ONE* 12:1-15.
55. Fraser TA, Bell MG, Harris PNA, Bell SC, Bergh H, Nguyen T-K, Kidd TJ, Nimmo GR, Sarovich DS, Price EP. 2019. Quantitative real-time PCR assay for the rapid identification of the intrinsically multidrug-resistant bacterial pathogen *Stenotrophomonas maltophilia*. *Microb Genom* 5:2-11.
56. Price EP, Dale JL, Cook JM, Sarovich DS, Seymour ML, Ginther JL, Kaufman EL, Beckstrom-Sternberg SM, Mayo M, Kaestli M, Glass MB, Gee JE, Wuthiekanun V, Warner JM, Baker A, Foster JT, Tan P, Tuanyok A, Limmathurotsakul D, Peacock SJ, Currie BJ, Wagner DM, Keim P, Pearson T. 2012. Development and validation of *Burkholderia pseudomallei*-specific real-time PCR assays for clinical, environmental or forensic detection applications. *PLoS One* 7:1-9.
57. Araujo P. 2009. Key aspects of analytical method validation and linearity evaluation. *J Chromatogr B Analyt Technol Biomed Life Sci* 877:2224-34.
58. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25:402-8.
59. Madden DE, Webb JR, Steinig EJ, Currie BJ, Price EP, Sarovich DS. 2021. Taking the next-gen step: Comprehensive antimicrobial resistance detection from *Burkholderia pseudomallei*. *EBioMedicine* 63:103152.
60. Wood DE, Lu J, Langmead B. 2019. Improved metagenomic analysis with Kraken 2. *Genome Biol* 20:257.
61. Pedersen BS, Quinlan AR. 2018. Mosdepth: quick coverage calculation for genomes and exomes. *Bioinformatics* 34:867-868.
62. Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, Philippon A, Allesoe RL, Rebelo AR, Florensa AF, Fagelhauer L, Chakraborty T, Neumann B, Werner G, Bender JK, Stingl K, Nguyen M, Coppens J, Xavier BB, Malhotra-Kumar S, Westh H, Pinholt M, Anjum MF, Duggett NA, Kempf I, Nykäsenoja S, Olkkola S, Wieczorek K, Amaro A, Clemente L, Mossong J, Losch S, Ragimbeau C, Lund O, Aarestrup FM. 2020. ResFinder 4.0 for predictions of phenotypes from genotypes. *Journal of Antimicrobial Chemotherapy* 75:3491-3500.
63. Juan C, Macia MD, Gutierrez O, Vidal C, Perez JL, Oliver A. 2005. Molecular mechanisms of β-lactam resistance mediated by AmpC hyperproduction in *Pseudomonas aeruginosa* clinical strains. *Antimicrob Agents Chemother* 49:4733-8.
64. Kong KF, Aguila A, Schneper L, Mathee K. 2010. Pseudomonas aeruginosa beta-lactamase induction requires two permeases, AmpG and AmpP. *BMC Microbiol* 10:328.

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

65. Tomás M, Doumith M, Warner M, Turton JF, Beceiro A, Bou G, Livermore DM, Woodford N. 2010. Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in *Pseudomonas aeruginosa* isolates from cystic fibrosis patients. *Antimicrob Agents Chemother* 54:2219-24.
66. Purssell A, Poole K. 2013. Functional characterization of the NfxB repressor of the *mexCD-oprJ* multidrug efflux operon of *Pseudomonas aeruginosa*. *Microbiology (Reading)* 159:2058-2073.
67. Livermore DM. 1995. Beta-Lactamases in laboratory and clinical resistance. *Clin Microbiol Rev* 8:557-84.
68. Rehman A, Jeukens J, Levesque RC, Lamont IL. 2021. Gene-gene interactions dictate ciprofloxacin resistance in *Pseudomonas aeruginosa* and facilitate prediction of resistance phenotype from genome sequence data. *Antimicrob Agents Chemother* 65:1-15.
69. Clark ST, Sinha U, Zhang Y, Wang PW, Donaldson SL, Coburn B, Waters VJ, Yau YCW, Tullis DE, Guttman DS, Hwang DM. 2019. Penicillin-binding protein 3 is a common adaptive target among *Pseudomonas aeruginosa* isolates from adult cystic fibrosis patients treated with β-lactams. *Int J Antimicrob Agents* 53:620-628.
70. Bolard A, Plésiat P, Jeannot K. 2018. Mutations in gene fusA1 as a novel mechanism of aminoglycoside resistance in clinical strains of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 62:1-10.
71. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC. 1997. Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of *Pseudomonas aeruginosa*. *Mol Microbiol* 23:345-54.
72. Feng X, Zhang Z, Li X, Song Y, Kang J, Yin D, Gao Y, Shi N, Duan J. 2019. Mutations in gyrB play an important role in ciprofloxacin-resistant Pseudomonas aeruginosa. *Infect Drug Resist* 12:261-272.
73. Higgins PG, Fluit AC, Milatovic D, Verhoef J, Schmitz FJ. 2003. Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa. *Int J Antimicrob Agents* 21:409-13.
74. Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S. 2009. Genomewide identification of genetic determinants of antimicrobial drug resistance in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 53:2522-31.
75. Colque CA, Albarracin Orio AG, Feliziani S, Marvig RL, Tobares AR, Johansen HK, Molin S, Smania AM. 2020. Hypermutator Pseudomonas aeruginosa Exploits Multiple Genetic Pathways To Develop Multidrug Resistance during Long-Term Infections in the Airways of Cystic Fibrosis Patients. *Antimicrob Agents Chemother* 64.
76. Zamorano L, Moya B, Juan C, Oliver A. 2010. Differential beta-lactam resistance response driven by *ampD* or *dacB* (PBP4) inactivation in genetically diverse *Pseudomonas aeruginosa* strains. *J Antimicrob Chemother* 65:1540-2.
77. Winstanley C, O'Brien S, Brockhurst MA. 2016. *Pseudomonas aeruginosa* evolutionary adaptation and diversification in cystic fibrosis chronic lung infections. *Trends Microbiol* 24:327-337.
78. Valderrey AD, Pozuelo MJ, Jiménez PA, Maciá MD, Oliver A, Rotger R. 2010. Chronic colonization by *Pseudomonas aeruginosa* of patients with obstructive lung diseases: cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. *Diagn Microbiol Infect Dis* 68:20-7.
79. Lee M, Hesek D, Blázquez B, Lastochkin E, Boggess B, Fisher JF, Mobashery S. 2015. Catalytic spectrum of the penicillin-binding protein 4 of *Pseudomonas aeruginosa*, a nexus for the induction of β-lactam antibiotic resistance. *J Am Chem Soc* 137:190-200.
80. Van den Bossche S, De Broe E, Coenye T, Van Braeckel E, Crabbé A. 2021. The cystic fibrosis lung microenvironment alters antibiotic activity: Causes and effects. *Eur Respir Rev* 30:1-16.
81. Vettoretti L, Plesiat P, Muller C, El Garch F, Phan G, Attree I, Ducruix A, Llanes C. 2009. Efflux unbalance in *Pseudomonas aeruginosa* isolates from cystic fibrosis patients. *Antimicrob Agents Chemother* 53:1987-97.

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

82. Goodman AL, Kulasekara B, Rietsch A, Boyd D, Smith RS, Lory S. 2004. A signaling network reciprocally regulates genes associated with acute infection and chronic persistence in *Pseudomonas aeruginosa*. *Dev Cell* 7:745-54.

83. Werner E, Roe F, Bugnicourt A, Franklin MJ, Heydorn A, Molin S, Pitts B, Stewart PS. 2004. Stratified growth in *Pseudomonas aeruginosa* biofilms. *Appl Environ Microbiol* 70:6188-96.

84. Murphy TF. 2008. The many faces of *Pseudomonas aeruginosa* in chronic obstructive pulmonary disease. *Clin Infect Dis* 47:1534-1536.

85. Quale J, Bratu S, Gupta J, Landman D. 2006. Interplay of efflux system, *ampC*, and *oprD* expression in carbapenem resistance of *Pseudomonas aeruginosa* clinical isolates. *Antimicrob Agents Chemother* 50:1633-1641.

86. Pai H, Kim J, Kim J, Lee JH, Choe KW, Gotoh N. 2001. Carbapenem resistance mechanisms in *Pseudomonas aeruginosa* clinical isolates. *Antimicrob Agents Chemother* 45:480-4.

87. Fung C, Naughton S, Turnbull L, Tingpej P, Rose B, Arthur J, Hu H, Harmer C, Harbour C, Hassett DJ, Whitchurch CB, Manos J. 2010. Gene expression of *Pseudomonas aeruginosa* in a mucin-containing synthetic growth medium mimicking cystic fibrosis lung sputum. *J Med Microbiol* 59:1089-1100.

88. Hill D, Rose B, Pajkos A, Robinson M, Bye P, Bell S, Elkins M, Thompson B, MacLeod C, Aaron SD, Harbour C. 2005. Antibiotic susceptibilities of *Pseudomonas aeruginosa* isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. *J of Clin Microbiol* 43:5085-5090.

89. Kirchner S, Fothergill JL, Wright EA, James CE, Mowat E, Winstanley C. 2012. Use of artificial sputum medium to test antibiotic efficacy against *Pseudomonas aeruginos*a in conditions more relevant to the cystic fibrosis lung. *J Vis Exp* 64:1-7.

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figures



Figure 1. *In vivo* expression of *Pseudomonas aeruginosa* antimicrobial resistance loci in six cystic fibrosis (CF) and five chronic obstructive pulmonary disease (COPD) sputa. Gene expression for each sample at each locus was first normalised against *rpsL* (ΔC_T); relative $\log_2$ fold-change expression was then determined by comparing ΔC_T values against COPD participant SCHI0070 (i.e. $\Delta\Delta C_T$), who was not receiving anti-pseudomonal antibiotics at the time of sputum collection. For SCHI0030, in which longitudinal sputa over antibiotic treatment were obtained, only the Day 0 sputum was used in this analysis to ensure independence of all observations. *, adjusted p <0.05; **, adjusted p <0.01; ***, adjusted p <0.001; ns, not significant. Error bars=95% confidence interval.

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 2. Differential expression (relative $\log_2$ fold change) of *Pseudomonas aeruginosa* antimicrobial resistance loci in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) sputa. Gene expression for each locus was first normalised against *rpsL* (ΔC_T); relative expression was then determined by comparing ΔC_T values against sputum from COPD participant SCHI0070 (i.e. $\Delta\Delta C_T$), who was not receiving anti-pseudomonal antibiotics at the time of sputum collection. For participants receiving anti-pseudomonal antibiotics, sputa are denoted by 'Day post-antibiotics' (D) (see Table 1 for details). Error bars, standard deviation. †Participants receiving non-pseudomonal antibiotics at the time of sputum collection.

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Tables

Table 1. *Pseudomonas aeruginosa*-positive sputa, corresponding derived isolates, disc diffusion profiles across 11 anti-pseudomonal antibiotics, and predicted antimicrobial resistance (AMR) phenotypes from whole-genome sequencing (WGS) and culturomic data.

Disease	Sputum ID[†]	Derived isolate ID	Aminoglycosides		Penicillins		Cephalosporins		FQs	Polymyxins		Carbapenems		Treatment	WGS variants (AMR phenotype)	Culturomic variants (AMR phenotype; proportion identified)
			AMK	TOB	PIP	TZP	CAZ	FEP	CIP	CST	PMB	IPM	MEM[#]			
CF	SCHI0002 (Day 8)	SCHI0002.S.8	S	S	R	I	I	R	I	S	S	R	S	IV CAZ, MEM, TOB	GyrB S466F (CIPi); OprD W339Ter (MEMr, IPMr); FtsI R504C (MEMr, IPMr, CAZr; FEPr, TZPr, PIPr)	NalD D187H (100%), PA1259 F273fs (PIPr; 38%), PA3127 loss (100%), GyrB E483D (CIPi; 8%), ParC S87W (CIPr; 10%), PA2198 R33fs (PIPr; 11%), PepA E363fs (PIPr; 14%), FdnH V215fs (PIPr; 12%)
		SCHI0002.S.9	R	S	R	R	R	R	I	S	S	R	R	IV CAZ, MEM, TOB	NalD D187H (CIPi, FEPi, CAZi, MEMi, IPMi); PA3127 loss (PIPr)	
	SCHI0002 (Day 329)	SCHI0002.S.12	R	R	R	R	R	R	I	S	S	S	S	IV CAZ, MEM, TOB	NalD D187H (CIPi, FEPi, CAZi, MEMi, IPMi); PA2326 loss (PIPr, FEPr); PA3127 loss (PIPr)	NalD D187H (100%)
	SCHI0010 (Day 7)	SCHI0010.S.1	R	R	R	R	R	R	R	S	S	R	R	IV CAZ, TOB	FusA1 A555E (AMKr, TOBr); GyrA T83I (CIPr); PA2693 D17fs (PIPr, TZPr, MEMr, FEPr, CAZr); PA2531 A137fs (PIPr); PckA G418fs (PIPr); *aac(6')-IIa* (TOBr)	FtsI H394R (61%), FusA1 A555E (100%), GyrA T83I (100%), PA2693 D17fs (100%), PA2531 A137fs (78%)
	SCHI0013 (Day 4)	SCHI0013.S.2	S	R	S	S	S	I	S	S	S	R	S	IV FOF, MEM	GyrB S466Y (CIPi), ParE A473V (CIPi), PA1942 loss (PIPr), MexE R229fs (CIPs); *ant(2'')-Ia* (TOBr)	OprD W6Ter (IPMr, MEMr; 22%), GyrB S466Y (96%), PA1942 loss (51%), PA3093 loss (PIPi; 15%), MexE R229fs (100%)
		SCHI0013.S.12	R	S	R	S	S	R	I	S	S	R	I	IV FOF, MEM	GyrB S466Y (CIPi); ParE A473V (CIPi); MexE R229fs (CIPs)	

	SCHI0018 (Day 8)	SCHI0018.S.11	S	R	R	I	R	I	S	S	S	S	---	IV CAZ, TZP, TOB	Not sequenced	ND
	SCHI0030 (Day 0)	SCHI0030.S.1	S	S	S	S	S	I	S	S	S	S	S	Nil	None	ND
	SCHI0030 (Day 6)	SCHI0030.S.2	R	R	R	R	R	R	I	S	S	R	R	IV ATM, TOB	PA1821 loss (PIPr, TZPr); MexF Y37Ter (CIPs); AmpD P42fs (CAZi, PIPi, TZPi, FEPi, IPMi, MEMi); FtsI R504C (MEMr, IPMr, CAZr, FEPr, TZPr, PIPr); GyrA D87H (CIPr)	ND
	SCHI0030 (Day 13)	SCHI0030.S.3	R	I	R	R	R	R	R	S	S	R	R	IV ATM, TOB	AmpD P42fs (CAZi, PIPi, TZPi, FEPi, MEMi, IPMi); OprD G193fs (MEMr, IPMr); MexF Y37Ter (CIPs); FtsI R504C (MEMr, IPMr, CAZr, FEPr, TZPr, PIPr); GyrA D87H (CIPr)	ND
	SCHI0030 (Day 50)*	SCHI0030.S.4	R	R	R	R	R	R	R	S	S	R	R	Nil	NfxB F126fs (CIPr, FEPr)	ND
		SCHI0030.S.5	S	S	S	S	S	S	S	S	S	S	S	Nil	None	
COPD	SCHI0038*	SCHI0038.S.2	I	R	S	S	S	S	S	S	S	S	S	Nil	Not sequenced	AmpG E592fs (100%)
		SCHI0038.S.3	S	S	S	S	S	S	S	S	S	S	S	Nil	AmpG E592fs (CAZs, FEPs, PIPs, TZPs)	
		SCHI0038.S.4	S	I	S	S	S	S	S	S	S	S	S	Nil	Not sequenced	
	SCHI0039*	SCHI0039.S.1	S	S	S	S	S	S	S	S	S	S	S	Nil	PA0090 R532_E535delinsQ (TZPr, FEPr, PIPr)	None
	SCHI0050 (Day 3)	SCHI0050.S.1	S	S	S	S	S	S	S	S	S	S	S	Oral CIP	ParC Q405R (precursor; causes CIPr in combination with a *gyrA* mutation)	ParC Q405R (100%)
	SCHI0065*	SCHI0065.S.1	S	S	S	S	S	S	S	S	S	S	S	Oral AZM	None	ND
	SCHI0070 (Day 2)*	SCHI0070.S.1	S	S	S	S	S	S	S	S	S	S	S	Oral AMC	None	ND
	SCHI0109	Not retrieved	---	---	---	---	---	---	---	---	---	---	---	Oral CIP and AZM; azathioprine	---	ND
Control	---	PAO1	S	S	S	S	S	S	S	S	S	S	S	---	None	NA

800 Abbreviations: AMK, amikacin; AMR, antimicrobial resistance; ATM, aztreonam; AZM, azithromycin; CAZ, ceftazidime; cDNA, complementary DNA; CF,
801 cystic fibrosis; CIP, ciprofloxacin; CST, colistin; COPD, chronic obstructive pulmonary disease; FEP, cefepime; FOF, fosfomycin; FQ, fluoroquinolones; fs,

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

802 frameshift; I or i, intermediate resistance; IPM, imipenem; MEM, meropenem; PMB, polymyxin B; PIP, piperacillin; R or r, antimicrobial resistant; S or s,
803 antimicrobial sensitive; TZP, piperacillin/tazobactam; TOB, tobramycin; AZM, azithromycin; AMC, amoxicillin/clavulanic acid

804 [†]Days since commencing antibiotics

805 *Not receiving anti-pseudomonal antibiotics at time of sputum collection

806 [#]MEM antibiotic resistance profiles were determined using E-TESTs

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

medRxiv preprint doi: https://doi.org/10.1101/2022.02.03.22270419; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 2. Primers and probes designed in this study.

Multiplex	Gene target	AMR target	Fluorophore	Oligo name	Oligo sequence (5'-3')	Optimised concentration (µM)
1	***mexY***	RND efflux pump	HEX	mexY-For	AAGAGGACCAGGGCGACTTC	0.20
				mexY-Rev	CTTCAGGGTGGCGAAGATCAT	0.20
				mexY-Probe	TGAAGCCGCCGACCGCA	0.20
	mexB	RND efflux pump	FAM	mexB-For	ACCGTGGTCCAGGTGATCG	0.15
				mexB-Rev	AGTTACTCTCCGAGGAGATGTAGCG	0.15
				mexB-Probe	CAGCAGATGAACGGGATCG	0.20
	ampC	β-lactamase	Texas Red	ampC-For	CTTCGACGGCATCAGCCT	0.45
				ampC-Rev	CCGATGCTCGGGTTGGA	0.45
				ampC-Probe	CAGATCCGCGACTACTACCGCCAGTG	0.20
	rpsL	Housekeeping gene	Cy5	rpsL-For	CGACAAGAGCGACGTGCC	0.25
				rpsL-Rev	TTACGCAGTGCCGAGTTCG	0.25
				rpsL-Probe	CATACGCCACGACGTTGCG	0.20
2	***mexC***	RND efflux pump	HEX	mexC-For	GTGCTGTTCGAGGCGCAG	0.20
				mexC-Rev	TCCTGCTGGCTGACCGC	0.20
				mexC-Probe	CTGGATCTTCACCAGCGGCT	0.25
	oprD	Porin	FAM	oprD-For	AAGTGGAGCGCCATTGCA	0.20
				oprD-Rev	TAGTAGTTGCGGAGCAGCAGGT	0.20
				oprD-Probe	CTGCTGTCTTCGATGAACC	0.20
	mexE	RND efflux pump	Texas Red	mexE-For	TACCTCGGCCTGAGCAGC	0.25
				mexE-Rev	GTTGACCTGGTTGTCGAGGAAG	0.25
				mexE-Probe	ACGGCAACCCGCACCTG	0.30

Abbreviations: AMR, antimicrobial resistant (allele); cDNA, complementary DNA; RND, resistance-nodulation-division; SNP, single-nucleotide polymorphism; WT, wild-type (allele)

*Bolded nucleotides indicate the SNP; underlined nucleotides indicate deliberately incorporated antepenultimate/penultimate mismatches to enhance allele specificity